Table 3.
DG | CA1 | EC | |||||||
---|---|---|---|---|---|---|---|---|---|
Neurons | Glia | Vessels | Neurons | Glia | Vessels | Neurons | Glia | Vessels | |
Control | 3 | 0 | 0.5 (0–1) | 3 | 0 (0–1) | 0.5 (0–1) | 3 | 0 | 0 (0–1) |
Acute | 12 (6–12)** | 12 (4–12)** | 8 (4–12)* | 12 (6–12)** | 12 (6–12)* | 8 (6–12)* | 12 (6–12)** | 9 (4–12)** | 8 (4–12)* |
Latent | 6* | 4 (4–6)* | 2 (1–2) | 6* | 4 (1–6)* | 2 (1–2) | 9* | 9 (6–9)* | 2 (1–4)* |
Chronic | 6 (6–9)** | 4 (1–9)** | 2 (1–6)* | 6 (6–9)** | 4 (1–9)* | 3 (1–6)* | 6 (6–9)** | 4 (1–9)** | 2 (1–6)* |
miR-155 in situ reactivity scores are given as median (minimum–maximum). This score is defined as intensity score (1 no; 2 weak; 3 moderate; 4 strong immunoreactivity) multiplied by relative number score (0 no; 1 single to 10%; 2 11–50%; 3 > 50%); DG, dentate gyrus; EC, entorhinal cortex; *p < 0.05, **p < 0.01